Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Conditions
Interventions
Ralinepag
Placebo
Locations
209
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
University of Arizona
Tucson, Arizona, United States
UCSD Health Sciences
La Jolla, California, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
Start Date
August 30, 2018
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
April 14, 2026
NCT05746039
NCT07218029
NCT03854071
NCT07073820
NCT07477197
NCT06899815
Lead Sponsor
United Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions